Outset Medical Bets on Margin Gains and Next-Gen Tableau

Outset Medical, Inc. ((OM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Outset Medical’s latest earnings call struck a cautiously optimistic tone, as management emphasized meaningful progress on margins, cash burn and product strategy despite a small revenue dip. Investors were urged to look past near‑term lumpiness in capital sales and focus on expanding gross margins, improving losses and a well‑funded balance sheet that supports the upcoming next‑generation Tableau launch.

Revenue Trends and Guidance Reaffirmed

Outset reported Q1 revenue of $27.9 million, down 6% year over year as capital orders shifted out of the quarter and product revenue fell 13% to $18.6 million. Even so, the company reaffirmed its 2026 revenue target of $125 million to $130 million, implying mid‑single‑digit to high‑single‑digit growth over 2025 and signaling confidence that demand will accelerate in the back half of this year.

Recurring Revenue Provides Stable Base

Recurring revenue from consumables and service reached $22.5 million in Q1 and remained roughly flat both sequentially and compared with last year. With recurring streams now representing about 70% of total revenue, Outset highlighted this mix as a stabilizing factor that helps cushion volatility from more unpredictable capital equipment sales.

Gross Margin Expansion Gains Traction

Non‑GAAP gross margin climbed 620 basis points year over year to 43.8%, driven by better manufacturing efficiency and an improving service business. Product gross margin rose to 52.4% from 48.4%, while service gross margin jumped to 26.7% from just 10.3%, underscoring operational improvements that management believes can carry margins toward a longer‑term 50% goal.

Advancing Toward Profitability

Non‑GAAP net loss narrowed to $15.4 million from $22.8 million a year ago, a 32% improvement that reflects rising margins and tight cost control. Non‑GAAP operating loss held steady at $13.4 million even as the company continued to invest in its platform, signaling that incremental scale is beginning to flow through to the bottom line.

Solid Cash Position and Reduced Cash Burn

Outset ended the quarter with $161 million in cash, cash equivalents and short‑term investments, providing a sizable buffer to fund growth initiatives. Management used about $12 million of cash in Q1 and now expects full‑year cash usage to be under $40 million, roughly 15% better than previous expectations and a key reassurance point for investors watching liquidity.

Next-Generation Tableau as Growth Catalyst

The company is preparing a limited release of its next‑generation Tableau system this quarter, with a broader ramp planned into Q3. Outset emphasized that the system is expected to be the first dialysis platform cleared under new FDA 2025 cybersecurity requirements, positioning it as a differentiated offering that management believes will stimulate demand and help drive second‑half revenue.

Commercial Leadership and Implementation Momentum

To support its growth ambitions, Outset appointed Derek Elliott as executive vice president of commercial, bringing additional experience to the sales organization. The company also pointed to fresh implementation wins, including a deployment across a roughly 400‑bed hospital system and planned Q2 go‑lives at more than 30 facilities involving nearly 200 consoles, evidencing traction in the field.

Leveraging Scale and Data Advantages

Outset underscored its installed base and data scale as strategic assets, noting that more than 1,000 facilities are now using Tableau. With over 3.5 million treatments delivered and more than 8 trillion data points stored in its cloud platform, the company sees opportunity to enhance analytics, improve workflow and drive product innovation that could deepen customer relationships over time.

Revenue Decline and Capital Sales Volatility

Despite the positive strategic narrative, Q1 underscored the sensitivity of results to capital order timing, as overall revenue fell from $29.8 million a year ago. Product revenue slid to $18.6 million and capital sales totaled $5.4 million, with management citing about $1 million of deals shifting out of the quarter and warning that such variability can create choppy quarter‑to‑quarter comparisons.

Lumpiness in Capital Orders and Mix Risk

Executives described capital demand as inherently lumpy and acknowledged that several late‑stage deals are expected to close later in the year, contributing to a back‑half‑loaded revenue profile. They also cautioned that as more consoles ship, the product and consumable mix could push gross margin toward the lower end of the guided range, underscoring some margin sensitivity even amid broader improvement.

Cost Discipline Amid Modest Expense Growth

Non‑GAAP operating expenses rose nearly 4% year over year to $25.6 million, reflecting investment in systems and personnel to support future growth. Management argued that these modest increases are being offset by margin expansion and improving unit economics, allowing the company to enhance capabilities without materially widening operating losses.

Dependence on Next-Gen Launch and Back-Half Weighting

Outset’s growth outlook leans heavily on the successful rollout and adoption of its next‑generation Tableau system, particularly as a cybersecurity‑focused differentiator. Any delays in launch, implementation or customer uptake could pressure the company’s second‑half revenue ramp and introduce risk to its reaffirmed longer‑term guidance.

Forward-Looking Guidance and Outlook

Management reaffirmed 2026 revenue guidance of $125 million to $130 million and guided full‑year non‑GAAP gross margin to the low‑ to mid‑40% range, versus Q1’s 43.8%. They expect only a modest step‑up in Q2, with most growth in Q3 and Q4 as next‑generation Tableau ramps, recurring revenue remains solid and the company moves toward a targeted 50% gross‑margin milestone while keeping annual cash use below $40 million.

Outset’s earnings call painted a picture of a company trading near‑term revenue volatility for structurally stronger margins, a healthier cash profile and a potentially differentiated product pipeline. For investors, the key watchpoints will be execution on the next‑generation Tableau launch and the timing of capital deals, but for now management’s confident tone and reaffirmed guidance suggest a measured but constructive outlook.